Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Quan V. Doan, PharmD

Genesis Research

Disclosure(s): AbbVie: Advisor/Consultant, Grant/Research Support; Allergan: Advisor/Consultant, Grant/Research Support

Poster(s):

1385 - Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET